What changed in this filing

/stocks — the workspaceLOADING

Item 1. Financial Statements

2026-07-29 compared with 2026-05-05 · 255 added, 210 removed, 847 unchanged (35% of the section changed)

4 unchanged sentences

(Dollars in thousands, except per share amounts)

Three Months Ended March 31,

Three Months Ended June 30, Six Months Ended June 30,

2026 2025 2026 2025

Total revenue, net $ 418,761 $ 415,605 $ 810,679 $ 798,258

4 unchanged sentences

Intangible asset amortization 3,770 3,754 7,546 7,458

Goodwill impairment charge — 511,365 — 511,365

Total costs and expenses 399,476 928,279 779,924 1,326,429

3 unchanged sentences

Other income (expense), net 4,186 ( 1,946 ) 8,665 ( 2,090 )

Loss before income taxes ( 2,409 ) ( 30,036 )

Provision for income taxes 2,208 ( 4,743 )

Net loss $ ( 4,617 ) $ ( 25,293 )

Net loss per share

Basic and diluted $ ( 0.06 ) $ ( 0.33 )

Income (loss) before income taxes 4,744 ( 530,952 ) 2,333 ( 560,988 )

Provision (benefit) for income taxes 262 ( 46,879 ) 2,467 ( 51,622 )

Net income (loss) $ 4,482 $ ( 484,073 ) $ ( 134 ) $ ( 509,366 )

Net income (loss) per share

Basic $ 0.06 $ ( 6.31 ) $ — $ ( 6.65 )

Diluted $ 0.06 $ ( 6.31 ) $ — $ ( 6.65 )

Weighted average common shares outstanding (See Note 12):

Basic and diluted 76,951 76,463

Basic 77,293 76,695 77,122 76,579

Diluted 78,168 76,695 77,122 76,579

Comprehensive loss (See Note 13)

4 unchanged sentences

(Dollars in thousands, except per share amounts)

March 31, 2026 December 31, 2025

June 30, 2026 December 31, 2025

Current assets:

39 unchanged sentences

240,000 authorized shares;

92,174 and 92,286 issued at March 31, 2026 and December 31, 2025, respectively

92,130 and 92,286 issued at June 30, 2026 and December 31, 2025, respectively

Additional paid-in capital 1,346,265 1,338,386

Treasury stock, at cost;

14,356 shares and 14,399 shares at March 31, 2026 and December 31, 2025, respectively

14,351 shares and 14,399 shares at June 30, 2026 and December 31, 2025, respectively

( 686,918 ) ( 689,210 )

7 unchanged sentences

(Dollars in thousands)

Three Months Ended March 31,

Six Months Ended June 30,

OPERATING ACTIVITIES:

2 unchanged sentences

Depreciation and amortization 76,565 74,880

Non-cash impairment charges — 511,365

Deferred income tax provision (benefit) ( 3,007 ) ( 46,663 )

20 unchanged sentences

Payments on debt ( 60,475 ) ( 31,131 )

Payment of debt issuance costs ( 275 ) ( 3,855 )

Purchases of treasury stock — ( 221 )

Payments for contingent considerations ( 6,842 ) ( 16,451 )

3 unchanged sentences

Effect of exchange rate changes on cash and cash equivalents ( 2,586 ) 17,207

Net increase (decrease) in cash and cash equivalents 1,761 ( 7,271 )

Net decrease in cash and cash equivalents ( 20,633 ) ( 28,461 )

Cash and cash equivalents at beginning of period 235,048 246,375

4 unchanged sentences

(Dollars in thousands)

Three Months Ended March 31, 2026

Six Months Ended June 30, 2026

Common Stock Treasury Stock Additional Paid-In Capital Accumulated Other Comprehensive Loss Retained Earnings Total Equity

7 unchanged sentences

Balance, March 31, 2026 92,174 $ 922 ( 14,356 ) $ ( 687,122 ) $ 1,340,722 $ ( 30,940 ) $ 418,824 $ 1,042,406

Three Months Ended March 31, 2025

Net Income — — — — — — 4,482 4,482

Other comprehensive loss, net of tax — — — — — ( 9,257 ) — ( 9,257 )

Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures ( 44 ) ( 1 ) 5 204 ( 417 ) — — ( 214 )

Share-based compensation

— — — — 5,960 — — 5,960

Balance, June 30, 2026 92,130 $ 921 ( 14,351 ) $ ( 686,918 ) $ 1,346,265 $ ( 40,197 ) $ 423,306 $ 1,043,377

Six Months Ended June 30, 2025

Common Stock Treasury Stock Additional Paid-In Capital Accumulated Other Comprehensive Loss Retained Earnings Total Equity

7 unchanged sentences

Balance, March 31, 2025 92,136 $ 921 ( 14,424 ) $ ( 690,379 ) $ 1,323,081 $ ( 24,106 ) $ 914,622 $ 1,524,139

Net loss — — — — — — ( 484,073 ) ( 484,073 )

Other comprehensive loss, net of tax — — — — — ( 6,801 ) — ( 6,801 )

Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures 201 2 8 345 ( 571 ) — — ( 224 )

Share-based compensation

— — — — 5,341 — — 5,341

Other adjustments — — — — 279 — — 279

Balance, June 30, 2025 92,337 923 ( 14,416 ) ( 690,034 ) 1,328,130 ( 30,907 ) 430,549 1,038,661

The accompanying unaudited notes are an integral part of these condensed consolidated financial statements.

3 unchanged sentences

The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise.

In the opinion of management, the March 31, 2026 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholders’ equity, results of operations and cash flows of the Company for the periods presented.

In the opinion of management, the June 30, 2026 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholders’ equity, results of operations and cash flows of the Company for the periods presented.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X.

1 unchanged sentence

The consolidated balance sheet as of December 31, 2025 was derived from audited financial statements but does not include all disclosures required by GAAP.

Operating results for the three-month period ended March 31, 2026 are not necessarily indicative of the results to be expected for the entire year.

Operating results for the three and six-month period ended June 30, 2026 are not necessarily indicative of the results to be expected for the entire year.

The preparation of consolidated financial statements is in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses.

32 unchanged sentences

Cash and cash equivalents

The Company had cash and cash equivalents, primarily consisting of cash on-hand, as well as time deposits with original maturities of three months or less and money market funds, which are highly liquid and readily convertible to cash, totaling approximately $ 236.8 million and $ 235.0 million at March 31, 2026 and December 31, 2025, respectively.

The Company had cash and cash equivalents, primarily consisting of cash on-hand, as well as time deposits with original maturities of three months or less and money market funds, which are highly liquid and readily convertible to cash, totaling $ 214.4 million and $ 235.0 million at June 30, 2026 and December 31, 2025, respectively.

Short-term investments

The Company had short-term investments, primarily consisting of time deposits with original maturities between three months and one year, totaling approximately $ 28.7 million and $ 28.7 million at March 31, 2026 and December 31, 2025, respectively.

The Company had short-term investments, primarily consisting of time deposits with original maturities between three months and one year, totaling $ 59.7 million and $ 28.7 million at June 30, 2026 and December 31, 2025, respectively.

The short-term investments are valued based on Level 1 measurements in the fair value hierarchy.

10 unchanged sentences

Any tariffs paid have been capitalized in inventory and have been recognized in cost of goods sold as those products subject to tariffs have been sold.

During the three months ended March 31, 2026, the Company applied the guidance within FASB Topic 405-20, Liabilities - Extinguishments of Liabilities (“ASC 405-20”).

In the first quarter of 2026, the Company applied the guidance within FASB Topic 405-20, Liabilities - Extinguishments of Liabilities (“ASC 405-20”).

As a result, the Company recognized a receivable of $ 19.0 million, recorded in other current assets, for tariffs previously paid on imported goods that are subject to refund.

1 unchanged sentence

These adjustments relate to the legal right to receive a refund of IEEPA tariffs previously imposed on the Company without appropriate authority.

During the six months ended June 30, 2026, the Company received cash refunds of $ 0.5 million, which reduced the receivable balance.

Employee termination benefits

During the three months ended March 31, 2026, the Company adopted a written severance plan that covers most U.S.

In the first quarter of 2026, the Company adopted a written severance plan that covers most U.S.

In situations outside the U.S., the Company has severance policies that meet or exceed the minimum statutory termination benefits requirements by country that must be paid to the affected employees.

7 unchanged sentences

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

The Company incurred employee termination costs on restructuring activities in the consolidated statement of operations for the three months ended March 31, 2026 and 2025.

The following table summarizes the activity in the restructuring related accrual balances included within accrued expenses and other current liabilities in the consolidated balance sheet for the three months ended March 31, 2026 and 2025.

Three Months Ended March 31,

The Company incurred employee termination costs on restructuring activities in the consolidated statement of operations for the six months ended June 30, 2026 and 2025.

Six Months Ended June 30,

(Dollars in thousands) 2026 2025

6 unchanged sentences

Segment information

During the three months ended March 31, 2026, the Company updated the allocation of certain cost and expense information from the Corporate and Other category to the Company’s two reportable segments to align with how the Company’s Chief Operating Decision Maker (“CODM”) reviews and manages the business.

In the first quarter of 2026, the Company updated the allocation of certain cost and expense information from the Corporate and Other category to the Company’s two reportable segments to align with how the Company’s Chief Operating Decision Maker (“CODM”) reviews and manages the business.

As a result of this update, the Company retrospectively recast prior period results, by segment, to conform to the current period presentation.

1 unchanged sentence

Segment and Geographic Information , for details of the reallocation of certain cost of goods sold and operating expense information to the Company’s reportable segments.

In addition, during the three months ended March 31, 2026, the Company renamed its Codman Specialty Surgical reportable segment to Specialty Surgery and its Tissue Technologies reportable segment to Tissue Reconstruction to better align with the reportable segments’ business activities, structures, and strategies.

In addition, during the first quarter of 2026, the Company renamed its Codman Specialty Surgical reportable segment to Specialty Surgery and its Tissue Technologies reportable segment to Tissue Reconstruction to better align with the reportable segments’ business activities, structures, and strategies.

The reportable segment name change did not result in any change to the composition of the reportable segments and has no impact on previously reported financial information.

ACQUISITIONS AND DIVESTITURES

Acquisition of Durepair®

On October 2, 2024, the Company completed the acquisition of the product rights for Durepair Regeneration Matrix (“Durepair”), a non-synthetic dura substitute for repair of the dura mater during neurosurgical procedures, from Medtronic plc for total consideration of $ 45.0 million.

The Company made cash payments of $ 10.0 million upon the closing of the acquisition in October 2024, $ 15.0 million on the first anniversary of the acquisition in October 2025, and will make an additional cash payment of $ 20.0 million upon the second anniversary of the acquisition in October 2026.

The additional cash payment to be made in October 2026 is included at its present value in accrued expenses and other current liabilities as of March 31, 2026.

The acquisition of the product rights for Durepair, which consist of certain patents and trademarks, regulatory approvals, and other records, has been accounted for as an asset acquisition in accordance with FASB Topic 805, Business Combinations (“ASC 805”) as the acquisition does not include an assembled workforce and substantially all of the fair value of the assets acquired is concentrated in a single identifiable intangible asset.

REVENUES FROM CONTRACTS WITH CUSTOMERS

Revenue From Contracts with Customers

Summary of Accounting Policies on Revenue Recognition

3 unchanged sentences

The Company has no significant multi-element contracts with customers.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Significant Estimates

9 unchanged sentences

The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Contract Assets and Liabilities

4 unchanged sentences

A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.

The following table summarizes the changes in the contract asset and liability balances for the three months ended March 31, 2026:

The following table summarizes the changes in the contract asset and liability balances for the six months ended June 30, 2026:

Dollars in thousands Total

3 unchanged sentences

Contract asset, net of transferred to trade receivables on contracts during the period $ 4,574

Contract asset, March 31, 2026

Contract asset, June 30, 2026

Contract Liability

3 unchanged sentences

Foreign currency translation $ 7

Contract liability, March 31, 2026

As of March 31, 2026, the short-term portion of the contract liability of $ 11.6 million, representing 52 % of unsatisfied or partially unsatisfied performance obligations, is expected to be recognized as revenue within 12 months and is included in current liabilities in the consolidated balance sheet.

Contract liability, June 30, 2026

As of June 30, 2026, the short-term portion of the contract liability of $ 11.7 million, representing 54 % of unsatisfied or partially unsatisfied performance obligations, is expected to be recognized as revenue within 12 months and is included in current liabilities in the consolidated balance sheet.

The long-term portion of $ 10.0 million, representing the remaining balance to be recognized thereafter, is included in other liabilities in the consolidated balance sheet.

3 unchanged sentences

The related shipping and freight charges incurred by the Company are included in the cost of goods sold.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Product Warranties

6 unchanged sentences

The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Disaggregated Revenue

The following table presents revenues disaggregated by the major sources of revenues for the three months ended March 31, 2026 and 2025 (dollar amounts in thousands):

Three Months Ended March 31, 2026 Three Months Ended March 31, 2025

The following table presents revenues disaggregated by the major sources of revenues for the three and six months ended June 30, 2026 and 2025 (dollar amounts in thousands):

Three Months Ended June 30, 2026 Three Months Ended June 30, 2025 Six Months Ended June 30, 2026 Six Months Ended June 30, 2025

Neurosurgery $ 213,264 $ 208,992 $ 411,458 $ 399,904

Instruments 47,233 50,950

ENT 37,707 38,802

Surgical Instruments 54,806 53,080 102,039 104,030

ENT Solutions 41,199 41,886 78,907 80,688

Total Specialty Surgery 309,269 303,958 592,404 584,622

Wound Reconstruction 79,648 74,779

Wound Reconstruction Solutions 81,305 84,747 160,952 159,526

Private Label 28,187 26,900 57,323 54,110

3 unchanged sentences

Inventories, net consisted of the following:

Dollars in thousands March 31, 2026 December 31, 2025

Dollars in thousands June 30, 2026 December 31, 2025

Finished goods $ 265,496 $ 262,614

3 unchanged sentences

Goodwill and Other Intangible Assets

Changes in the carrying amount of goodwill for the three-month period ended March 31, 2026 were as follows:

Changes in the carrying amount of goodwill for the six-month period ended June 30, 2026 were as follows:

Dollars in thousands Specialty Surgery Tissue Reconstruction Total

1 unchanged sentence

Foreign currency translation ( 2,245 ) ( 1,767 ) ( 4,012 )

Goodwill at March 31, 2026

Goodwill at June 30, 2026

$ 341,922 $ 269,223 $ 611,145

In accordance with FASB Topic 350, Intangibles—Goodwill and Other (“ASC 350”), goodwill is not subject to amortization but is tested for impairment at the reporting unit level annually in the third quarter.

Additionally, the Company may perform interim tests of goodwill for impairment if an event occurs or circumstances change that could potentially reduce the fair value

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

of a reporting unit below its carrying amount.

Additionally, the Company may perform interim tests of goodwill for impairment if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit below its carrying amount.

The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units.

4 unchanged sentences

The quantitative test uses a combination of both an income approach and a market approach to determine the fair value of the reporting unit.

The income approach utilizes the estimated discounted cash flows for the reporting unit, while the market approach utilizes comparable publicly-traded companies’ revenue and earnings before interest, taxes, depreciation, and amortization (“EBITDA”) multiples.

The income approach utilizes the estimated discounted cash flows for the reporting unit, while the market approach utilizes comparable publicly-traded companies’ revenue and earnings

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

before interest, taxes, depreciation, and amortization (“EBITDA”) multiples.

Estimates and assumptions used in the income approach to calculate projected future discounted cash flows included revenue growth rates, cost of sales, terminal growth rates, and a discount rate for each reporting unit.

15 unchanged sentences

Therefore, it was not necessary to perform a quantitative impairment test.

During the three months ended March 31, 2026, the Company observed a decline in the market valuation of the Company’s common stock along with a volatile macroeconomic environment due to continuing tensions in global trade relationships and the ongoing military conflict between the U.S., Israel, and Iran.

As a result, the Company has evaluated whether an event has occurred or circumstances changed that could potentially reduce the fair value of a reporting unit below its carrying amount as of March 31, 2026, and determined it was not more likely than not that the fair values of the Tissue Reconstruction and Neurosurgery reporting units was less than their respective carrying values.

The Company will continue to evaluate changes in events and circumstances which could impact this conclusion in the future, including quantitative and qualitative factors such as the Company’s market capitalization or macroeconomic conditions affecting the Company’s forecast results.

If an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit below its carrying amount, the Company will perform an interim assessment of goodwill for impairment.

The Company will also continue to monitor conditions that may require the Company to perform an interim assessment of its intangible assets for impairment.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Other Intangible Assets

The components of the Company’s identifiable intangible assets were as follows:

March 31, 2026

June 30, 2026

Dollars in thousands Weighted

19 unchanged sentences

$ 1,992,731 $ ( 858,068 ) $ 1,134,663

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Intangible Assets with Indefinite Lives

14 unchanged sentences

Definite-lived intangible assets are periodically evaluated for impairment in accordance with FASB Topic 360, Property, Plant and Equipment (“ASC 360”) whenever events or changes in circumstances indicate that a definite-lived intangible asset’s carrying value may not be recoverable.

Total amortization of intangible assets for the three months ended March 31, 2026 was $ 27.0 million.

Of this amount, $ 23.2 million was related to amortization of technology based intangibles and included in cost of goods sold.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Total amortization of intangible assets for the three months ended March 31, 2025 was $ 26.5 million.

Of this amount, $ 22.8 million was related to amortization of technology based intangibles and included in cost of goods sold.

Total amortization of intangible assets for the three and six months ended June 30, 2026 was $ 27.0 million and $ 54.0 million, respectively.

Of this amount, $ 23.2 million and $ 46.4 million, respectively, was related to amortization of technology based intangibles and included in cost of goods sold.

Total amortization of intangible assets for the three and six months ended June 30, 2025 was $ 26.8 million and $ 53.3 million, respectively.

Of this amount, $ 23.0 million and $ 45.8 million, respectively, was related to amortization of technology based intangibles and included in cost of goods sold.

Based on quarter-end exchange rates, amortization expense (including amounts reported in cost of goods sold) is expected to be approximately $ 53.7 million for the remainder of 2026, $ 106.5 million in 2027, $ 102.9 million in 2028, $ 97.6 million in 2029, $ 91.5 million in 2030, $ 88.5 million in 2031 and $ 358.6 million thereafter.

4 unchanged sentences

subsidiaries, excluding intangible assets.

The Senior Credit Facility is subject to various financial and negative covenants and, at March 31, 2026, the Company was in compliance with all such covenants.

The Senior Credit Facility is subject to various financial and negative covenants and, at June 30, 2026, the Company was in compliance with all such covenants.

On June 6, 2025, in response to the risks and uncertainties surrounding the Company’s future results of operations due to tariffs, the Company entered into the June 2025 Amendment of the Senior Credit Facility (the “June 2025 Amendment”) with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent.

1 unchanged sentence

Under the terms of the June 2025 Amendment, the Company’s Consolidated Total Leverage Ratio (defined, as of any date of determination, as the ratio of (a) Consolidated Funded Indebtedness as of such date (as defined in the Senior Credit Facility) less cash that is not subject to any restriction on the use or investment thereof to (b) Consolidated EBITDA (as defined in the Senior Credit Facility)) for the period of four consecutive fiscal quarters ending on such date was modified to the following:

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Fiscal Quarter Ending Maximum Consolidated Total Leverage Ratio

14 unchanged sentences

the one-month Term SOFR plus 1.00 %.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

The applicable rates are based on the Company’s Consolidated Total Leverage Ratio for the period of four consecutive fiscal quarters ending on such date.

4 unchanged sentences

The terms of the Senior Credit Facility limit the amount of dividends the Company may pay.

At March 31, 2026 and December 31, 2025, there wa s $ 1,075.0 million and $ 1,045.0 million, respectively, ou tstanding under the revolving credit facility component of the Senior Credit Facility.

At March 31, 2026 and December 31, 2025, there was $ 716.9 million and $ 726.6 million outstanding under the term loan component of the Senior Credit Facility at a weighted average interest rate of 5.9 % and 5.7 %, respectively.

As of March 31, 2026 and December 31, 2025 there was $ 38.8 million of the term loan component of the Senior Credit Facility classified as current on the condensed consolidated balance sheet.

The fair value of the term loan component and revolving credit facility component of the Senior Credit Facility at March 31, 2026 was $ 713.4 million, and $ 1,069.5 million, respectively.

The fair value was determined by using a discounted cash flow model based on current market interest rates available to the Company.

These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy.

Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable i nputs that reflect unadjusted quoted prices for identical assets or liabilities.

As of March 31, 2026 and December 31, 2025, letters of credit outstanding to taled $ 3.0 million.

There were no amounts drawn under the letters of credit outstanding as of March 31, 2026.

At June 30, 2026 and December 31, 2025, there wa s $ 1,075.0 million and $ 1,045.0 million, respectively, ou tstanding under the revolving credit facility component of the Senior Credit Facility and $ 707.2 million and $ 726.6 million, respectively, outstanding under the term loan component of the Senior Credit Facility.

The weighted average interest rate on the outstanding borrowings under the Senior Credit Facility was 5.4 % and 5.7 %, respectively.

As of June 30, 2026 and December 31, 2025, there was $ 43.6 million and $ 38.8 million, respectively, of the term loan component of the Senior Credit Facility classified as current on the condensed consolidated balance sheet.

As of June 30, 2026 and December 31, 2025, letters of credit outstanding to taled $ 3.0 million.

There were no amounts drawn under the letters of credit outstanding as of June 30, 2026.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Contractual repayments of the term loan component of the Senior Credit Facility are due as follows:

As of March 31, 2026

As of June 30, 2026

Principal Repayment

6 unchanged sentences

Convertible Senior Notes

The Company’s 0.5 % Convertible Senior Notes due 2025 (the “2025 Notes”) issued in February 2020 pursuant to an indenture, dated as of February 7, 2020 (the “Original Indenture”), between the Company and Citibank, N.A., as trustee, matured on August 15, 2025.

The Company’s 0.5 % Convertible Senior Notes due 2025 (the “2025 Notes”) issued in February 2020 pursuant to an indenture, dated as of February 7, 2020, between the Company and Citibank, N.A., as trustee, matured on August 15, 2025.

The 2025 Notes were settled upon maturity for $ 575.0 million in cash, excluding accrued interest, funded by borrowings on the revolving credit facility component of the Senior Credit Facility.

No shares were issued to settle the 2025 Notes.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

In connection with the issuance of the 2025 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of the 2025 Notes (the “hedge participants”).

12 unchanged sentences

An occurrence of an event of default or a termination event under this Securitization Agreement may give rise to the right of its counterparty to terminate this facility.

As of March 31, 2026, the Company was in compliance with the covenants and none of the termination events had occurred.

At March 31, 2026 and December 31, 2025, the Company had $ 76.4 million and $ 87.8 million, respectively, of outstanding borrowings under its Securitization Facility with an interest rate of 4.7 % and 4.8 %, respectively.

The fair value of the outstanding borrowing of the Securitization Facility at March 31, 2026 was $ 73.1 million.

These fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company.

These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy.

As of June 30, 2026, the Company was in compliance with the covenants and none of the termination events had occurred.

On April 10, 2026, the Company entered into an amendment to the Securitization Facility Agreement with a syndicate of lending banks with PNC Bank, N.A., as Administrative Agent (the “2026 Securitization Facility Amendment”).

2 unchanged sentences

The Company incurred approximately $ 0.3 million of new issuance costs associated with the 2026 Securitization Facility Amendment which will be amortized over the remaining term of the Securitization Agreement as amended.

At June 30, 2026 and December 31, 2025, the Company had $ 92.6 million and $ 87.8 million, respectively, of outstanding borrowings under its Securitization Facility with an interest rate of 5.0 % and 4.8 %, respectively.

Debt Issuance Costs

Debt issuance costs associated with the Senior Credit Facility (other than the revolving credit facility component) are presented as a reduction to the carrying value of the related debt.

Debt issuance costs associated with the revolving credit facility component of the Senior Credit Facility are capitalized within other long-term assets on the consolidated balance sheet.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Debt issuance costs associated with the Senior Credit Facility (other than the revolving credit facility component) are presented as a reduction to the carrying value of the related debt.

Debt issuance costs associated with the revolving credit facility component of the Senior Credit Facility are capitalized within other long-term assets on the consolidated balance sheet.

Estimated Fair Value of Debt Measurements

The carrying amounts and the estimated fair values of debt as of March 31, 2026 and December 31, 2025 are as follows:

March 31, 2026 December 31, 2025

The carrying amounts and the estimated fair values of debt as of June 30, 2026 and December 31, 2025 are as follows:

June 30, 2026 December 31, 2025

Fair Value Measurement Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value

13 unchanged sentences

Additionally, the Company entered into a basis swap where the Company receives Term SOFR and pays daily compounded SOFR to convert the portfolio of swaps from daily compounded SOFR to Term SOFR.

The Company held the following interest rate swaps as of March 31, 2026 and December 31, 2025 (dollar amounts in thousands):

March 31, 2026 December 31, 2025 March 31, 2026 December 31, 2025

The Company held the following interest rate swaps as of June 30, 2026 and December 31, 2025 (dollar amounts in thousands):

June 30, 2026 December 31, 2025 June 30, 2026 December 31, 2025

Hedged Item Notional Amount Effective Date Termination Date Fixed Interest Rate Estimated Fair Value

10 unchanged sentences

Related gain/loss amounts recognized in AOCI and earnings are presented in the Effects of Derivative Instruments table below.

The estimated gain that is expected to be reclassified to interest income from AOCI as of March 31, 2026 within the next twelve months is $ 17.4 million.

The estimated gain that is expected to be reclassified to interest income from AOCI as of June 30, 2026 within the next twelve months is $ 20.2 million.

The Company has designated these derivative instruments as cash flow hedges.

29 unchanged sentences

As the principal outstanding decreases on the intercompany loans, the aggregate notional amount of the related cross-currency swaps will decrease by a corresponding amount.

The Company held the following cross-currency rate swaps as of March 31, 2026 and December 31, 2025 (dollar amounts in thousands):

March 31, 2026 December 31, 2025 March 31, 2026 December 31, 2025

The Company held the following cross-currency rate swaps as of June 30, 2026 and December 31, 2025 (dollar amounts in thousands):

June 30, 2026 December 31, 2025 June 30, 2026 December 31, 2025

Effective Date Termination Date Fixed Rate Aggregate Notional Amount Fair Value

11 unchanged sentences

Related gain/loss amounts recognized in AOCI and earnings are presented in the Effects of Derivative Instruments table below.

The estimated gain that is expected to be reclassified to other income (expense), net from AOCI as of March 31, 2026 within the next twelve months is $ 10.0 million.

For the three months ended March 31, 2026 and 2025, the Company recorded a gain of $ 5.9 million and a loss of $( 9.4 ) million, respectively, in other income, net related to change in fair value related to the foreign currency rate translation to offset the gains and losses, respectively, recognized on the intercompany loans.

For the three months ended March 31, 2026 and 2025, the Company recorded gains of $ 3.5 million and $ 1.2 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.

The estimated gain that is expected to be reclassified to other income (expense), net from AOCI as of June 30, 2026 within the next twelve months is $ 10.1 million.

For the three and six months ended June 30, 2026, the Company recorded gains of $ 7.2 million and $ 13.1 million, respectively, in other income, net related to change in fair value related to the foreign currency rate translation to offset the gains and losses, respectively, recognized on the intercompany loans.

For the three and six months ended June 30, 2025, the Company recorded losses of $( 40.6 ) million and $( 49.8 ) million, respectively, in other income, net related to change in fair value related to the foreign currency rate translation to offset the gains and losses, respectively, recognized on the intercompany loans.

For the three and six months ended June 30, 2026, the Company recorded gains of $ 3.5 million and $ 7.0 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.

For the three and six months ended June 30, 2025, the Company recorded gains of $ 2.3 million and $ 3.5 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.

Net Investment Hedges

4 unchanged sentences

The new cross-currency swap agreement was designated as a net investment hedge to partially offset the effects of foreign currency on foreign subsidiaries.

On July 25, 2025, the Company entered into a cross-currency swap agreement with a notional amount of CHF 59.7 million, equivalent to $ 75.0 million, where the Company agreed with third-parties to sell CHF in exchange for U.S.

In July 2025, the Company entered into a cross-currency swap agreement with a notional amount of CHF 59.7 million, equivalent to $ 75.0 million, where the Company agreed with third-parties to sell CHF in exchange for U.S.

dollars at a specified rate at the maturity of the contract.

The new cross-currency swap agreement was designated as a net investment hedge to partially offset the effects of foreign currency on foreign subsidiaries.

The Company held the following cross-currency rate swaps designated as net investment hedges as of March 31, 2026 and December 31, 2025, respectively (dollar amounts in thousands):

March 31, 2026 December 31, 2025 March 31, 2026 December 31, 2025

The Company held the following cross-currency rate swaps designated as net investment hedges as of June 30, 2026 and December 31, 2025, respectively (dollar amounts in thousands):

June 30, 2026 December 31, 2025 June 30, 2026 December 31, 2025

Effective Date Termination Date Fixed Rate Aggregate Notional Amount Fair Value

13 unchanged sentences

Related gain/loss amounts recognized in AOCI and earnings are presented in the Effects of Derivative Instruments table below.

The estimated gain that is expected to be reclassified to interest income from AOCI as of March 31, 2026 within the next twelve months is $ 11.1 million.

The estimated gain that is expected to be reclassified to interest income from AOCI as of June 30, 2026 within the next twelve months is $ 10.7 million.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

3 unchanged sentences

These contracts typically settle at various dates within twelve months of execution.

As of March 31, 2026, the notional amount of foreign currency forward contracts was CHF 14.1 million.

As of June 30, 2026, the notional amount of foreign currency forward contracts was CHF 19.6 million.

The foreign currency forward contracts are carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in AOCI.

The changes in fair value will be recognized into earnings as a component of cost of sales when the forecasted-transaction occurs.

For the three months ended March 31, 2026 and 2025, amounts reclassified to earnings included (i) the effective hedge component amounts of $ 0.5 million and $ 0.2 million, respectively, within cost of goods sold, and (ii) forward‑points amortization of $( 0.1 ) million and $( 0.2 ) million, respectively, within other income (expense), net.

For the three months ended June 30, 2026 and 2025, amounts reclassified to earnings included (i) the effective hedge component amounts of $ 0.3 million and $( 0.4 ) million, respectively, within cost of goods sold, and (ii) forward‑points amortization of $( 0.2 ) million and $( 0.2 ) million, respectively, within other income (expense), net.

For the six months ended June 30, 2026 and 2025, amounts reclassified to earnings included (i) the effective hedge component amounts of $ 0.8 million and an immaterial amount, respectively, within cost of goods sold, and (ii) forward‑points amortization of $( 0.3 ) million and $( 0.4 ) million, respectively, within other income (expense), net.

Related gain/loss amounts recognized in AOCI and earnings are presented in the Effects of Derivative Instruments table below.

On April 28, 2026, the Company entered into foreign currency forwards with a notional amount of CHF 3.1 million to be designated as a cash flow hedge to mitigate the exchange rate risk of CHF-denominated intercompany purchases.

These contracts settle at various dates within twelve months of execution.

Counterparty Credit Risk

8 unchanged sentences

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of March 31, 2026 and December 31, 2025:

The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of June 30, 2026 and December 31, 2025:

Fair Value as of

Location on Balance Sheet (1) :

March 31, 2026 December 31, 2025

June 30, 2026 December 31, 2025

Dollars in thousands

29 unchanged sentences

Effects of Derivative Instruments

The following presents the effect of derivative instruments designated as cash flow hedges and net investment hedges on the accompanying condensed consolidated statement of operations during the three months ended March 31, 2026 and 2025:

Dollars in thousands Balance in AOCI

6 unchanged sentences

Statements of

Three Months Ended March 31, 2026

Three Months Ended June 30, 2026

Cash Flow Hedges

5 unchanged sentences

$ ( 67,889 ) $ 10,352 $ 17,641 $ ( 75,178 )

Three Months Ended March 31, 2025

Three Months Ended June 30, 2025

Cash Flow Hedges

5 unchanged sentences

$ ( 10,927 ) $ ( 97,134 ) $ ( 34,078 ) $ ( 73,983 )

Dollars in thousands Balance in AOCI

Year Amount of

Recognized in

AOCI Amount of Gain (Loss)

Reclassified from

Earnings Balance in AOCI

End of Quarter Location in

Statements of

Six Months Ended June 30, 2026

Cash Flow Hedges

Interest rate swap $ 27,247 $ 11,111 $ 8,717 $ 29,641 Interest expense

Cross-currency swap ( 6,583 ) 10,777 18,724 ( 14,530 ) Other income (expense), net

Foreign currency forward contract 727 ( 999 ) 534 ( 806 ) Cost of sales

Net Investment Hedges

Cross-currency swap ( 93,141 ) 9,862 6,204 ( 89,483 ) Interest income

$ ( 71,750 ) $ 30,751 $ 34,179 $ ( 75,178 )

Six Months Ended June 30, 2025

Cash Flow Hedges

Interest rate swap $ 48,794 $ ( 10,883 ) $ 2,860 $ 35,051 Interest expense

Cross-currency swap ( 11,621 ) ( 49,537 ) ( 46,391 ) ( 14,767 ) Other income (expense), net

Foreign currency forward contract ( 624 ) $ 2,103 $ ( 427 ) 1,906

Net Investment Hedges

Cross-currency swap ( 31,130 ) ( 59,311 ) 5,732 ( 96,173 ) Interest income

$ 5,419 $ ( 117,628 ) $ ( 38,226 ) $ ( 73,983 )

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Derivative Instruments not Designated Hedges

1 unchanged sentence

These contracts typically settle at various dates within twelve months of execution.

As of March 31, 2026, the notional amounts totaled CNH 30.0 million, CHF 4.0 million, and EUR 7.0 million equivalent to $ 4.4 million, $ 5.1 million, and $ 8.2 million, respectively.

As of June 30, 2026, the notional amounts totaled CNH 90.0 million, CHF 12.0 million, and EUR 5.0 million equivalent to $ 13.3 million, $ 15.1 million, and $ 5.8 million, respectively.

In 2021, the Company entered into a foreign currency swap, with a notional amount of JPY 800.0 million, equivalent to $ 7.3 million, to mitigate the risk from fluctuations in foreign currency exchange rates associated with an intercompany loan denominated in Japanese yen.

1 unchanged sentence

The notional amount of each currency is exchanged at the inception and termination of the currency swap by each party.

The Company subsequently paid down a portion of this swap, bringing the notional amount down to JPY 400.0 million, equivalent to $ 3.6 million as of March 31, 2026.

The fair value of the foreign currency swaps not designated as hedges was $ 1.3 million and $ 1.0 million as of March 31, 2026 and December 31, 2025, respectively.

In connection with the settlement of the related intercompany loan, the Company fully settled and unwound the derivative during the second quarter of 2026.

The fair value of the foreign currency swaps not designated as hedges was $( 0.5 ) million and $ 1.0 million as of June 30, 2026 and December 31, 2025, respectively.

The following table summarizes the gains and losses on derivative instruments not designated as hedges on the condensed consolidated statements of income, which was included in other income:

Dollars in thousands Three Months Ended March 31,

Dollars in thousands Three Months Ended June 30, Six Months Ended June 30,

2026 2025 2026 2025

Foreign currency forward contracts 399 ( 1,869 ) 177 ( 1,695 )

1 unchanged sentence

Total $ 378 $ ( 2,020 ) $ 102 $ ( 1,677 )

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Stock Based Compensation

As of March 31, 2026, the Company had stock options, restricted stock awards, performance stock units and restricted stock units outstanding under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the “2003 Plan”).

As of June 30, 2026, the Company had stock options, restricted stock awards, performance stock units and restricted stock units outstanding under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the “2003 Plan”).

Stock options issued under the 2003 Plan become exercisable over specified periods, generally within four years from the date of grant for officers and employees, within one year from date of grant for directors which generally expire eight years from the grant date for employees, and from six to ten years for directors and certain executive officers, except in certain instances that result in accelerated vesting due to death, disability, retirement age or change-in-control provisions within their grant agreements.

3 unchanged sentences

Stock Options

As of March 31, 2026, there were approximately $ 4.0 million of total unrecognized compensation costs related to unvested stock options.

As of June 30, 2026, there were approximately $ 8.2 million of total unrecognized compensation costs related to unvested stock options.

These costs are expected to be recognized over a weighted-average period of approximately three years .

There were no stock options granted during the three months ended March 31, 2026.

There were 765,840 stock options granted during the six months ended June 30, 2026.

For the six months ended June 30, 2026, the weighted average grant date fair value for stock options granted was $ 8.28 per option.

Restricted Stock and Performance Stock

2 unchanged sentences

The Company expenses the fair value of restricted stock awards and restricted stock units on a straight-line basis over the requisite service period.

As of March 31, 2026, there was approximately $ 54.2 million of total unrecognized compensation costs related to these unvested awards.

As of June 30, 2026, there was approximately $ 44.4 million of total unrecognized compensation costs related to these unvested awards.

The Company expects to recognize these costs over a weighted-average period of approximately two years .

The Company granted 2,397,075 restricted stock units and 1,149,357 performance stock units during the three months ended March 31, 2026.

For the three months ended March 31, 2026, the weighted average grant date fair value for restricted stock units and performance stock units granted was $ 9.79 and $ 9.61 per award, respectively.

The Company granted 2,909,403 restricted stock units and 1,149,357 performance stock units during the six months ended June 30, 2026.

For the six months ended June 30, 2026, the weighted average grant date fair value for restricted stock units and performance stock units granted was $ 10.74 and $ 9.61 per award, respectively.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

The Company also maintains an Employee Stock Purchase Plan (the “ESPP”), which provides eligible employees with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions.

2 unchanged sentences

The Company has various defined benefit plans which cover certain employees in France, Japan, Germany and Switzerland.

Net periodic benefit costs for the Company’s defined benefit pension plans for the three months ended March 31, 2026 were $ 0.4 million.

The components of the net periodic benefit costs other than the service cost component of $ 1.0 million for the three months ended March 31, 2026 are included in other income, net in the consolidated statements of operations.

Net periodic benefit costs for the Company’s defined benefit pension plans for the three months ended March 31, 2025 were $ 0.4 million.

The components of the net periodic benefit costs other than the service cost component of $ 0.8 million for the three months ended March 31, 2025 are included in other income, net in the consolidated statements of operations.

The estimated fair values of plan assets were $ 71.1 million and $ 71.7 million as of March 31, 2026 and December 31, 2025, respectively.

The net plan assets of the pension plans are invested in common trusts as of March 31, 2026 and December 31, 2025.

Net periodic benefit costs for the Company’s defined benefit pension plans for the three and six months ended June 30, 2026 were $ 0.4 million and $ 0.9 million.

The components of the net periodic benefit costs other than the service cost component of $ 1.0 million and $ 2.0 million for the three and six months ended June 30, 2026 are included in other income, net in the consolidated statements of operations.

Net periodic benefit costs for the Company’s defined benefit pension plans for the three and six months ended June 30, 2025 were $ 0.4 million and $ 0.7 million.

The components of the net periodic benefit costs other than the service cost component of $ 0.8 million and $ 1.6 million for the three and six months ended June 30, 2025 are included in other income, net in the consolidated statements of operations.

The estimated fair values of plan assets were $ 69.7 million and $ 71.7 million as of June 30, 2026 and December 31, 2025, respectively.

The net plan assets of the pension plans are invested in common trusts as of June 30, 2026 and December 31, 2025.

Common trusts are classified as Level 2 in the fair value hierarchy.

3 unchanged sentences

The Company maintains a deferred compensation plan in which certain employees of the Company may defer the payment and taxation of up to 75 % of their base salary and up to 100 % of bonus amounts and other eligible cash compensation.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

This deferred compensation is invested in funds offered under this plan and is valued based on Level 1 measurements in the fair value hierarchy.

Assets of the Company’s deferred compensation plan are included in other current assets and recorded at fair value based on their quoted market prices.

The fair value of these assets were $ 7.3 million and $ 7.9 million as of March 31, 2026 and December 31, 2025, respectively.

The fair value of these assets were $ 8.1 million and $ 7.9 million as of June 30, 2026 and December 31, 2025, respectively.

Offsetting liabilities relating to the deferred compensation plan are included in other liabilities.

1 unchanged sentence

The Company leases administrative, manufacturing, research and distribution facilities, equipment and vehicles through operating lease agreements.

The Company has no finance leases as of March 31, 2026.

The Company has no finance leases as of June 30, 2026.

Many of the Company’s facility leases include both lease (e.g., fixed payments including rent) and non-lease components (e.g., common-area or other maintenance costs).

4 unchanged sentences

As most of the Company’s leases do not provide an implicit rate, the Company uses a collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments.

Total operating lease expense for the three months ended March 31, 2026 and March 31, 2025 was $ 6.4 million and $ 5.9 million, respectively, which includes $ 0.1 million in related party operating lease expense.

Total operating lease expense for the six months ended June 30, 2026 and June 30, 2025 was $ 13.0 million and $ 11.9 million, respectively, which includes $ 0.1 million in related party operating lease expense.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Supplemental balance sheet information related to operating leases were as follows:

Dollars in thousands, except lease term and discount rate March 31, 2026 December 31, 2025

Dollars in thousands, except lease term and discount rate June 30, 2026 December 31, 2025

ROU assets $ 137,085 $ 140,568

10 unchanged sentences

Leased equipment 6.2 % 6.9 %

Supplemental cash flow information related to leases for the three months ended March 31, 2026 and 2025 were as follows:

Dollars in thousands March 31, 2026 March 31, 2025

Supplemental cash flow information related to leases for the six months ended June 30, 2026 and 2025 were as follows:

Dollars in thousands June 30, 2026 June 30, 2025

Cash paid for amounts included in the measurement of lease liabilities:

2 unchanged sentences

Operating leases $ 3,475 $ 1,635

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Future minimum lease payments under operating leases at March 31, 2026 were as follows:

Future minimum lease payments under operating leases at June 30, 2026 were as follows:

Dollars in thousands Related Parties Third Parties Total

12 unchanged sentences

Long-term lease liabilities 162,660

There were no future minimum lease payments under finance leases at March 31, 2026.

There were no future minimum lease payments under finance leases at June 30, 2026.

Related Party Leases

2 unchanged sentences

The current lease agreement also provides (i) a 5-year renewal option for the Company to extend the lease from November 1, 2029 through October 31, 2034 at the fair market rental rate of the premises, and (ii) another 5-year renewal option to extend the lease from November 1, 2034 through October 31, 2039 at the fair market rental rate of the premises.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Treasury Stock

As of March 31, 2026 and December 31, 2025, there were 14.4 million and 14.4 million shares of treasury stock outstanding with a cost of $ 687.1 million and $ 689.2 million, respectively, at a weighted average cost per share of $ 47.86 for both periods.

As of June 30, 2026 and December 31, 2025, there were 14.4 million and 14.4 million shares of treasury stock outstanding with a cost of $ 686.9 million and $ 689.2 million, respectively, at a weighted average cost per share of $ 47.86 for both periods.

On December 31, 2025, the Company’s share repurchase program expired.

2 unchanged sentences

The following table provides a summary of the Company’s effective tax rate:

Three Months Ended March 31,

Three Months Ended June 30, Six Months Ended June 30,

2026 2025 2026 2025

Reported tax rate 5.5 % 8.8 % 105.7 % 9.2 %

The Company’s effective income tax rates for the three months ended March 31, 2026 and 2025 were ( 91.7 )% and 15.8 %, respectively.

For the three months ended March 31, 2026, the Company’s effective tax rate was primarily driven by a $ 2.9 million tax expense related to a shortfall from stock-based compensation, due to market conditions.

For the three months ended March 31, 2025, the Company’s effective tax rate was driven by federal, state, and international tax benefits generated from operating losses in certain jurisdictions, offset by a $ 2.1 million tax expense related to a shortfall from stock-based compensation.

Changes to income tax laws and regulations, in any of the tax jurisdictions in which the Company operates, could impact the effective tax rate.

Various governments, both U.S.

and non-U.S., are increasingly focused on tax reform and revenue-raising legislation.

On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted in the U.S., with certain provisions effective in 2025 and others implemented through 2027.

The OBBBA included the permanent extension of certain expiring provisions of the 2017 Tax Cuts and Jobs Act, the immediate expensing of previously capitalized research and development costs, and reduced limitations on interest expense deductions, among other provisions.

The Company’s effective income tax rates for the three months ended June 30, 2026 and 2025 were 5.5 % and 8.8 %, respectively.

The 2026 effective tax rate was primarily impacted by tax benefits associated with returns filed in certain foreign jurisdictions, as well as the jurisdictional mix of income, including its impact on the Company’s net Controlled Foreign Corporation tested income (“NCTI”) inclusion, formerly referred to as Global Intangible Low Taxed Income (“GILTI”).

The 2025 effective tax rate was primarily impacted by a partially non-deductible goodwill impairment charge, NCTI, and additional taxes related to global minimum tax requirements in certain foreign jurisdictions, partially offset by tax benefits from operating losses in certain jurisdictions.

The Company’s effective income tax rates for the six months ended June 30, 2026 and 2025 were 105.7 % and 9.2 %, respectively.

The 2026 effective tax rate was primarily impacted by tax expense related to a shortfall from stock-based compensation due to market conditions, partially offset by a tax benefit from returns filed in certain foreign jurisdictions.

The 2025 effective tax rate was primarily impacted by a partially non-deductible goodwill impairment charge, GILTI, and additional taxes related to global minimum tax requirements in certain foreign jurisdictions, partially offset by tax benefits from operating losses in certain jurisdictions.

Changes in tax laws or regulations in the jurisdictions in which the Company operates could impact its effective tax rate.

Governments in the U.S.

and abroad continue to focus on tax reform and revenue-raising legislation.

On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”), was enacted in the U.S.

The OBBBA includes several tax law changes, including extensions of certain 2017 Tax Cuts and Jobs Act provisions, immediate expensing of certain research and development costs, and changes to interest expense deduction limitations.

The Company continues to monitor tax legislation enacted by foreign jurisdictions in response to the Organization of Economic Cooperation and Development's (“OECD”) Pillar Two global minimum tax framework.

Pillar Two generally provides for a 15% minimum tax on large multinational companies on a jurisdiction-by-jurisdiction basis, with certain provisions effective beginning in 2024.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Further, the Company continues to monitor legislation in foreign jurisdictions, enacted in response to ongoing efforts led by the Organization of Economic Cooperation and Development (“OECD”).

The OECD released Pillar Two model rules, defining a new 15% global minimum tax for each jurisdiction in which a multinational corporation operates, effective beginning in 2024.

NET LOSS PER SHARE

Net Income (loss) Per Share

Basic and diluted net loss per share was as follows:

Three Months Ended March 31,

Three Months Ended June 30, Six Months Ended June 30,

Dollars in thousands, except per share amounts 2026 2025 2026 2025

Basic net loss per share:

Net loss $ ( 4,617 ) $ ( 25,293 )

Basic net income (loss) per share:

Net income (loss) $ 4,482 $ ( 484,073 ) $ ( 134 ) $ ( 509,366 )

Weighted average common shares outstanding 77,293 76,695 77,122 76,579

Basic net loss per common share $ ( 0.06 ) $ ( 0.33 )

Diluted net loss per share:

Net loss $ ( 4,617 ) $ ( 25,293 )

Basic net income (loss) per common share $ 0.06 $ ( 6.31 ) $ — $ ( 6.65 )

Diluted net income (loss) per share:

Net income (loss) $ 4,482 $ ( 484,073 ) $ ( 134 ) $ ( 509,366 )

Weighted average common shares outstanding — Basic 77,293 76,695 77,122 76,579

2 unchanged sentences

Weighted average common shares for diluted earnings per share 78,168 76,695 77,122 76,579

Diluted net loss per common share $ ( 0.06 ) $ ( 0.33 )

Diluted net income (loss) per common share $ 0.06 $ ( 6.31 ) $ — $ ( 6.65 )

Basic earnings per share is computed by dividing net income by the weighted-average common shares outstanding during the period.

3 unchanged sentences

For periods in which the Company generated a net loss, the Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive.

Common stock of approximately 1.6 million and 1.6 million shares at March 31, 2026 and 2025, res pectively, were not included in the computation of diluted net income and diluted net loss per share, respectively, because their effect would have been anti-dilutive.

Common stock of approximately 1.8 million and 1.5 million shares at June 30, 2026 and 2025, res pectively, were not included in the computation of diluted net income and diluted net loss per share, respectively, because their effect would have been anti-dilutive.

Accumulated Other Comprehensive Loss

Comprehensive loss for the three months ended March 31, 2026 and 2025:

Three Months Ended March 31,

Comprehensive loss for the three and six months ended June 30, 2026 and 2025:

Three Months Ended June 30, Six Months Ended June 30,

Dollars in thousands 2026 2025 2026 2025

Net loss $ ( 4,617 ) $ ( 25,293 )

Net income (loss) $ 4,482 $ ( 484,073 ) $ ( 134 ) $ ( 509,366 )

Foreign currency translation adjustment ( 3,413 ) ( 3,445 ) ( 3,889 ) 8,186

Change in unrealized (gain) loss on derivatives, net of tax ( 220 ) ( 8,016 )

Change in unrealized gain on derivatives, net of tax ( 5,645 ) ( 3,190 ) ( 5,865 ) ( 11,206 )

Pension liability adjustment, net of tax ( 199 ) ( 166 ) ( 366 ) ( 316 )

2 unchanged sentences

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Changes in accumulated other comprehensive loss by component between December 31, 2025 and March 31, 2026 are presented in the table below, net of tax:

Changes in accumulated other comprehensive loss by component between December 31, 2025 and June 30, 2026 are presented in the table below, net of tax:

Dollars in thousands Gains and Losses on Derivatives Defined Benefit Pension Items Foreign Currency Items Total

4 unchanged sentences

Net current-period other comprehensive (loss) ( 5,865 ) ( 366 ) ( 3,889 ) ( 10,120 )

Balance at March 31, 2026

Balance at June 30, 2026

$ 10,083 $ 4,618 $ ( 54,898 ) $ ( 40,197 )

For the three months ended March 31, 2026, the Company reclassified gains of $ 7.3 million and $ 5.7 million from AOCI to other income and interest income, respectively.

For the six months ended June 30, 2026, the Company reclassified gains of $ 15.8 million and $ 11.5 million from AOCI to other income and interest income, respectively.

Additionally, the Company reclassified a loss of $ 0.4 million from AOCI to cost of goods sold.

1 unchanged sentence

The Company is organized primarily on the basis of products and operates two global reportable segments.

Resources are allocated and performance is assessed by the Company’s President and Chief Executive Officer, which the Company has determined to be the Chief Operating Decision Maker (“CODM”).

During the three months ended March 31, 2026, the Company renamed its two reportable segments to better align with the reportable segments’ business activities, structures, and strategies.

Resources are allocated and performance is assessed by the Company’s President and Chief Executive Officer, which the Company has determined to be the CODM.

During the six months ended June 30, 2026, the Company renamed its two reportable segments to better align with the reportable segments’ business activities, structures, and strategies.

The reportable segment name change did not result in any change to the composition of the reportable segments and has no impact on previously reported financial information.

1 unchanged sentence

• The Specialty Surgery reportable segment operations consist of (i) the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment;

(ii) the Instruments business, which sells more than 40,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices;

and (iii) the ENT business, which includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, as well as surgical navigation systems.

• The Tissue Reconstruction reportable segment operations consists of the Wound Reconstruction business, which sells offerings such as skin and wound repair, plastics and surgical reconstruction products and nerve and tendon repair products.

(ii) the Surgical Instruments business, which sells more than 40,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices;

and (iii) the ENT Solutions business, which includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, as well as surgical navigation systems.

• The Tissue Reconstruction reportable segment operations consists of the Wound Reconstruction Solutions business, which sells offerings such as skin and wound repair, plastics and surgical reconstruction products and nerve and tendon repair products.

The Tissue Reconstruction segment also includes the Company’s private label business which performs contract manufacturing for third parties.

The Corporate and Other category includes a portion of various executive, finance, human resource, information systems and legal functions which are not allocated to the reportable segments.

During the three months ended March 31, 2026, the Company updated the allocation of certain cost and expense information that the CODM regularly reviews to evaluate performance for decision-making purposes from the Corporate and Other category to the Company’s reportable segments to align with how the CODM reviews and manages the business.

During the six months ended June 30, 2026, the Company updated the allocation of certain cost and expense information that the CODM regularly reviews to evaluate performance for decision-making purposes from the Corporate and Other category to the Company’s reportable segments to align with how the CODM reviews and manages the business.

As a result of this update, the Company retrospectively recast prior period results, by reportable segment, to conform to the current period presentation.

5 unchanged sentences

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Net sales and profit by each reportable segment for the three months ended March 31, 2026 and 2025 are as follows:

Three Months Ended March 31, 2026

Dollars in thousands Specialty Surgery Tissue Reconstruction Corporate and Other Total

Net sales and profit by each reportable segment for the three and six months ended June 30, 2026 and 2025 are as follows:

Three Months Ended June 30, 2026 Six Months Ended June 30, 2026

Dollars in thousands Specialty Surgery Tissue Reconstruction Corporate and Other Total Specialty Surgery Tissue Reconstruction Corporate and Other Total

Total revenue, net $ 309,269 $ 109,492 $ — $ 418,761 $ 592,404 $ 218,275 $ — $ 810,679

8 unchanged sentences

Other income, net 4,186 8,665

Loss before income taxes $ ( 2,409 )

Three Months Ended March 31, 2025

Dollars in thousands Specialty Surgery Tissue Reconstruction Corporate and Other Total

Income before income taxes $ 4,744 $ 2,333

Three Months Ended June 30, 2025 Six Months Ended June 30, 2025

Dollars in thousands Specialty Surgery Tissue Reconstruction Corporate and Other Total Specialty Surgery Tissue Reconstruction Corporate and Other Total

Total revenue, net $ 303,958 $ 111,647 $ — $ 415,605 $ 584,622 $ 213,636 $ — $ 798,258

6 unchanged sentences

Intangible asset amortization — — 3,754 3,754 — — 7,458 7,458

Goodwill impairment 388,106 123,259 — 511,365 388,106 123,259 — 511,365

Total cost and expenses 606,150 230,999 91,130 928,279 814,595 328,544 183,290 1,326,429

Operating income (loss) $ 72,221 $ 4,443 $ ( 92,161 ) ( 15,497 )

Operating loss $ ( 302,192 ) $ ( 119,352 ) ( 91,130 ) ( 512,674 ) $ ( 229,973 ) $ ( 114,908 ) $ ( 183,290 ) ( 528,171 )

Interest income 4,710 9,130

2 unchanged sentences

Loss before income taxes $ ( 530,952 ) $ ( 560,988 )

(1) The amounts reported for the three months ended March 31, 2025 have been retrospectively recast to reflect the realignment of certain cost and expense information as discussed in Note 1.

(1) The amounts reported for the three and six months ended June 30, 2025 have been retrospectively recast to reflect the realignment of certain cost and expense information as discussed in Note 1.

Basis of Presentation .

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

The Company does not allocate any assets to the reportable segments.

2 unchanged sentences

Total revenue by major geographic area consisted of the following:

Three Months Ended March 31,

Three Months Ended June 30, Six Months Ended June 30,

Dollars in thousands 2026 2025 2026 2025

4 unchanged sentences

Total Revenues $ 418,761 $ 415,605 $ 810,679 $ 798,258

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Commitments and Contingencies

24 unchanged sentences

On March 16, 2026, the plaintiffs filed their Supplemental Amended Complaint, in response to which the Company filed its Supplemental Motion to Dismiss on April 3, 2026.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

On May 13, 2025 and May 16, 2025, derivative lawsuits captioned Leverett v.

9 unchanged sentences

These derivative actions have stayed pending resolution of the motion to dismiss in the Pembroke litigation.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Contractual Payment Obligations

In connection with the Company’s October 2024 acquisition of Durepair Regeneration Matrix (“Durepair”), the Company has a remaining contractual obligation to make a cash payment of $ 20.0 million in October 2026.

The obligation is recorded at its present value within accrued expenses and other current liabilities as of June 30, 2026.

Contingent Consideration

The Company determined the fair value of contingent consideration during the three month period ended March 31, 2026 and March 31, 2025 to reflect the change in estimate, additions, payments, transfers and the time value of money during each period.

A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the three months ended March 31, 2026 and March 31, 2025 is as follows (in thousands):

Three Months Ended March 31, 2026 Contingent Consideration Liability Related to the Acquisition of:

The Company determined the fair value of contingent consideration during the six month period ended June 30, 2026 and June 30, 2025 to reflect the change in estimate, additions, payments, transfers and the time value of money during each period.

A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the six months ended June 30, 2026 and June 30, 2025 is as follows (in thousands):

Six Months Ended June 30, 2026 Contingent Consideration Liability Related to the Acquisition of:

Derma Sciences (2)

4 unchanged sentences

Change in fair value of contingent consideration liabilities 661 4 ( 1,438 ) ( 773 )

Balance as of March 31, 2026

Balance as of June 30, 2026

6,960 354 — 7,314

2 unchanged sentences

Total 6,960 354 — 7,314

Three Months Ended March 31, 2025 Contingent Consideration Liability Related to the Acquisition of:

Six Months Ended June 30, 2025 Contingent Consideration Liability Related to the Acquisition of:

Derma Sciences (2)

4 unchanged sentences

Change in fair value of contingent consideration liabilities ( 627 ) ( 1,451 ) — 1,875 ( 203 )

Balance as of March 31, 2025

Balance as of June 30, 2025

$ 7,341 $ 1,235 $ 3 $ 37,800 46,379

6 unchanged sentences

Selling, general and administrative

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Arkis BioSciences Inc.

12 unchanged sentences

Surgical Innovations Associates, Inc.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

As part of the acquisition of Surgical Innovations Associates, Inc.

1 unchanged sentence

The Company estimated the fair value of the contingent consideration for the revenue based milestone to be $ 32.6 million at the acquisition date and $ 25.0 million for the PMA approval milestone at the acquisition date.

In the second quarter of 2025, the Company paid out $ 18.1 million related to the 2024 performance year.

Similarly, in the second quarter of 2024, the Company paid out $ 12.4 million related to the 2023 performance year.

The Company calculated the remaining milestone payment for the 2025 performance year based on actual sales for the year ended December 31, 2025 and expects to make the 2025 performance year payment, totaling $ 18.1 million, in the second quarter of 2026.

The Company used probabilities of achieving the conditions to calculate the fair value of the contingent consideration for the PMA approval milestone.

The Company disbursed $ 17.9 million in the second quarter of 2026 for the 2025 performance year.

Similarly, in the second quarter of 2025, the Company disbursed $ 18.1 million related to the 2024 performance year, and in the second quarter of 2024, the Company paid out $ 12.4 million related to the 2023 performance year.

As of June 30, 2026, there were no amounts payable under the PMA approval milestone, as FDA approval of the PMA application had not been obtained by the applicable milestone date.

Fair Value Measurements

12 unchanged sentences

Assets and Liabilities Measured at Fair Value on a Recurring Basis

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

The Company has investments in time deposits that are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices, as well as certain debt obligations that are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

7 unchanged sentences

Commitments and Contingencies for additional information on these contingent consideration liabilities.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Assets and liabilities measured and recorded at fair value on a recurring basis as of March 31, 2026 and December 31, 2025 consisted of the following:

Assets and liabilities measured and recorded at fair value on a recurring basis as of June 30, 2026 and December 31, 2025 consisted of the following:

Dollars in thousands Fair Value

Measurement March 31, 2026 December 31, 2025

Measurement June 30, 2026 December 31, 2025

Cash and cash equivalents Level 1 $ 214,415 $ 235,048

9 unchanged sentences

Contingent consideration Level 3 7,314 26,049

Foreign currency forward contracts (not designated as hedges) Level 2 452 —

Total Liabilities:

$ 141,835 $ 167,915

There were no transfers into or out of Level 3 during the three months ended March 31, 2026 and 2025.

There were no transfers into or out of Level 3 during the three and six months ended June 30, 2026 and 2025.

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

2 unchanged sentences

Other than the fair value estimates disclosed in Note 4.

Acquisitions and Divestitures , Note 5.

Goodwill and Other Intangible Assets , and Note 9.

Leases and Related Party Leases , there were no non-recurring fair value measurements during the three months ended March 31, 2026 and 2025.

Leases and Related Party Leases , there were no non-recurring fair value measurements during the three and six months ended June 30, 2026 and 2025.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Subsequent Events

On July 17, 2026, the Company’s manufacturing facility in Cincinnati, Ohio sustained flood damage as a result of severe weather conditions.

The flooding caused damage to the facility, equipment, inventory and other assets and resulted in operational disruptions at the site.

The Company is currently evaluating the extent of the damage and has not completed its assessment of the financial impact of the event.

At the date the financial statements were issued, the Company is unable to reasonably estimate the total losses that may be incurred.

The Company maintains insurance coverage for property damage and business interruption losses and is actively working with its insurance carriers to assess available coverage and potential recoveries.

Because the event occurred after the balance sheet date, the accompanying condensed consolidated financial statements do not reflect any adjustments related to this event.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1. Financial Statements